Warning: The NCBI web site requires JavaScript to function. more...

An official website of the United States government

Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Account

Logged in as:
username

Dashboard
Publications
Account settings
Log out

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

MeSH

NLM Controlled Vocabulary

Search database

Search term

Limits
Advanced
Help

Full

Format

Full
Full (text)
Summary
Summary (text)

Send to:

Choose Destination

File
Clipboard
Collections

Format

Gemifloxacin

A naphthyridine and fluoroquinolone derivative antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used for the treatment of community-acquired pneumonia and acute bacterial infections associated with chronic bronchitis.

Year introduced: 2019 (1997)

PubMed search builder options

Subheadings:

administration and dosage
adverse effects
agonists
analogs and derivatives
analysis
antagonists and inhibitors
blood
cerebrospinal fluid
chemical synthesis

chemistry
classification
economics
history
immunology
isolation and purification
metabolism
pharmacokinetics

pharmacology
poisoning
radiation effects
standards
supply and distribution
therapeutic use
toxicity
urine

Restrict to MeSH Major Topic.

Do not include MeSH terms found below this term in the MeSH hierarchy.

Tree Number(s): D03.633.100.612.250, D03.633.100.810.835.322.322

MeSH Unique ID: D000077735

Registry Number: OKR68Y0E4T

Entry Terms:

SB-265805
SB265805
SB 265805
LB 20304
LB-20304
LB20304
Gemifloxacin Mesylate
Factive
7-(3-aminomethyl-4-methoxyimino-pyrrolidine-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-(1,8)-naphthyridine-3-carboxylic acid

Pharmacologic Action: